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Role of Monocarboxylate Anion Transporter 8 (MCT8) in
Thyroid Hormone Transport: Answers from Mice
The physiological significance of thyroid hormone trans-
porters in the cell membrane has been demonstrated recently
with the identification of mutations in the human monocar-
boxylate anion transporter 8 (MCT8) (1) (2). Mutations of this
transporter are associated with a form of X-linked mental
retardation, severe neurological impairment, and an unusual
pattern of thyroid hormone concentrations in blood. As de-
scribed by Dumitrescu et al. in this issue of Endocrinology (3),
deletion of the Mct8 gene in mice faithfully reproduces the
altered thyroid hormone concentrations observed in pa-
tients, although no obvious signs of neurological impairment
are observed in the mutant mice. The altered thyroid hor-
mone concentrations in blood and tissues seem to be due to
the simultaneous elevation in the activity of deiodinases type
1 (D1) and 2 (D2) as a consequence of tissue-specific thyroid
hormone availability consequent to different dependency on
Mct8 for thyroid hormone uptake.
Until recently, the mechanism of thyroid hormone entry
into cells was not clear. It was assumed that the lipophilic
nature of thyroid hormones facilitated passive diffusion
through the lipid bilayer. In support of this idea was the lack
of evidence for saturable transport after administration of
graded doses of thyroid hormones in vivo. However, specific
transport mechanisms could be demonstrated for T4 and T3
in a variety of cultured cellular systems. Kinetic properties of
high-affinity membrane transporters were described and
later on characterized as distinct molecular entities (for a
review see Ref. 4). The membrane transporters for thyroid
hormones belong to several families including the Na-de-
pendent organic anion transporter, the Na-independent
organic anion transporting polypeptides, the heterodimeric
amino acid transporters, and the MCTs. These transporters
have a wide range of tissue distribution, with overlapping
patterns of expression in most of them.
The important role of the transporters in thyroid patho-
physiology received strong support with the identification of
patients harboring mutations of the MCT8. The MCT8 gene
is located in the X chromosome and encodes a 12-segment
transmembrane protein expressed in brain, liver, kidney,
thyroid, heart, pituitary, and other tissues. So far it is known
to be specific for iodothyronines, with higher affinity for T3
than for T4 (5). The patients with mutations of this gene are
affected by a form of an X-linked mental retardation syn-
drome combined with an unusual pattern of circulating thy-
roid hormones, with high T3 and low T4 and rT3. The neu-
rological impairment is present in early infancy and includes
global developmental delay with poor head control, mental
retardation, and various degrees of motor abnormalities in-
cluding spastic quadriplegia.
Inactivating mutations of theMCT8 gene could explain the
thyroid phenotype as a consequence of the restricted passage
of T4 and T3 to cells. Results in vitro showed that cultured skin
fibroblasts isolated from the patients had a decreased uptake
of both T4 and T3 (6). D2 activity was increased up to 8-fold
in the cells, an expected consequence of decreased availabil-
ity of T4, which regulates D2 degradation through the pro-
teasome pathway (7). The authors proposed that increased
conversion of T4 to T3 in tissues, together with a decreased
T3 reuptake, was responsible for the decreased circulating T4
and increased T3. Deficient uptake of T3 by neurons could
also provide an explanation for the thyroid syndrome as well
as being the determinant cause for the neurological impair-
ment in patients. In the brain, most T3 is formed locally by
D2-mediated conversion of T4 to T3. This enzyme is pre-
dominantly expressed in glial cells, namely astrocytes and
third ventricle tanycytes (8). It is likely that the passage of T4,
and T3, to astrocytes through the blood-brain barrier is not
affected in the patients because the brain endothelial cells
express another transporter, from the Na-independent or-
ganic anion transporting polypeptides family. However,
MCT8 is expressed in neurons and, therefore, neuronal up-
take of T3 is likely to be impaired in the patients (9). In
addition, because neurons express the inactivating type 3
deiodinase (D3), which degrades T3 to T2, decreased degra-
dation of T3 could also account for the elevated blood levels
of this hormone.
The Mct8 knockout mice generated by Dumitrescu et al.
and reported in this issue (3) are an excellent tool to analyze
the pathophysiology of the syndrome. The most important
observation is that, indeed, deletion of the Mct8 gene leads
to thyroid function abnormalities similar to those observed
in the humans. Male mice with the genotype Mct8/y have
elevated T3 and reduced T4 and rT3 in blood. Importantly,
Mct8/ females present similar abnormalities, discarding
any gender-specific differences that could influence the phe-
notype. The authors compare the effect of different doses of
T3 administered to the wild-type and the mutant mice. Sev-
eral conclusions could be drawn from these experiments.
First, the authors demonstrate a relative pituitary resistance
to thyroid hormone, because a higher dose of T3 was needed
to suppress TSH in the mutant mice than in the wild-type
mice. This experiment indicates that the effect of T3 on TSH
suppression requires transport through Mct8. Actually the
transporter is expressed in the anterior pituitary, though not
in hormone producing, but in stellate cells (10). Second, they
showed that the elevated T3 levels are due primarily to in-
creased production from T4. The reason is that, in the T3-
treated mice, basal concentrations of T3 and the disappear-
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ance rate of the hormone in serum and liver were similar in
mutant and wild-type mice, in a situation where T4 was
undetectable in both strains of mice. Therefore, T4 is needed
to maintain the high T3 concentration in the mutant mice.
Indeed, a crucial aspect of the thyroid phenotype of the
mutant mice is the coexistence of “hyperthyroid” and “hy-
pothyroid” tissues, leading to a simultaneous elevation of D1
and D2 activities, respectively, in those tissues. In the liver,
where transporters other than Mct8 are expressed, the ele-
vation of circulating T3 induces a clear thyrotoxic state, as
shown by markers of thyroid hormone action in this organ.
D1, a sensitive marker of thyroid status in the liver, was
up-regulated. The elevated activity of this enzyme further
contributes to the syndrome by increasing conversion of T4
to T3 and increasing degradation of rT3.
D2 activity was highly increased in the brain, as a response
to cellular hypothyroidism. The highly increased D2 activity
in brain is likely due to the decreased availability of T4 to the
astrocytes secondary to a decreased circulating T4. The con-
tribution of the brain to the thyroid syndrome is complex. D2
and Mct8 are expressed in different cells (9), and entry of T4
and T3 to D2-expressing astrocytes through the blood-brain
barrier should, in principle, not be compromised, as it takes
place through a different transporter. An elevation of D2
activity in these cells should be a late event in the syndrome,
following the decreased T4 supply. Another type of D2-ex-
pressing cells, the tanycytes, also express Mct8. These cells
presumably get T4 from the cerebrospinal fluid, via the cho-
roid plexus, a site of prominent Mct8 expression. Therefore,
it is likely that tanycyte D2 is increased in the early phases
of the syndrome, but its possible contribution to the syn-
drome is unknown.
The contribution of D2 expressed in other tissues such as
the heart, muscle, or skin is probably also relevant to explain
the role played by D2 in the initial phases of the syndrome,
through a mechanism of increased T3 production and de-
creased T3 reuptake, as described above.
The role of D3 is not clear. It appears likely that a restriction
in T3 transport to cells expressing D3 could explain the el-
evation of T3 concentrations through decreased degradation.
Such a restricted transport of T3 was demonstrated by the
lack of D3 induction in Mct8/y mice treated with T3. How-
ever, the data show that, under conditions of undetectable T4
in the plasma, the concentrations reached by T3 at different
times after administration were not different in normal than
in the mutant mice.
Despite that Mct8 deletion reproduced the thyroid phe-
notype in mice, no obvious signs of neurological distur-
bances were observed. The mice seem to behave normally,
without obvious motor abnormalities. Of course, a more
detailed behavioral evaluation is needed. As pointed out by
the authors (3), in mice it is difficult to reproduce other
situations resulting from decreased thyroid hormone supply
to the human brain. In terms of basal T3 concentration, the
brains of the mutant mice are probably not as strongly hy-
pothyroid, as in other situations such as Pax8 deletion (11).
The secondary increase in D2 activity may provide sufficient
T3 to normalize basal expression of T3-regulated genes and
prevent the harmful effects of unliganded T3 nuclear receptor
(12, 13).
In conclusion, the findings by Dumitrescu et al. (3) repre-
sent an important step forward in understanding the role of
the transporters in thyroid hormone distribution and action
and the pathogenesis of the X-linked mental retardation syn-
drome caused by MCT8 mutations in humans.
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